#cd70-protein-targeting
#cd70-protein-targeting
[ follow ]
#immunotherapy #autoimmune-diseases #car-t-therapy #clinical-trials #car-t-cell-therapy #solid-tumors
fromwww.nature.com
6 days agoEngineered immunosuppressive dendritic cells protect against cardiac remodelling
Chronic inflammation is a central driver of pathological fibrosis after ischaemic or haemodynamic stress, but strategies that locally rebalance injurious and reparative immune responses without systemic immunosuppression are lacking.
Medicine
Medicine
fromwww.scientificamerican.com
4 weeks agoA silent immune attack on the kidney could be treated by new drugs, if it can be found early
IgA nephropathy is an autoimmune kidney disease affecting up to 40 percent of patients with eventual dialysis or transplant needs, but emerging precision therapies can preserve kidney function if diagnosed early.
OMG science
fromHarvard Gazette
2 months agoWhy did that cancer cell become drug-resistant? - Harvard Gazette
TimeVault records and stores cellular gene-expression history inside living cells, enabling retrieval of past gene-activity information to study differentiation, stress responses, adaptation, and drug resistance.
fromwww.nature.com
1 month agoAuthor Correction: The genomic landscape of response to EGFR blockade in colorectal cancer
In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK (P-ERK) levels in a MAP2K1-mutant patient-derived xenograft (PDX) exposed to the MEK inhibitor AZD6244 (AZD). However, this image was accidentally overlaid with a micrograph from Extended Data Fig. 10 (left column, panel PAN), which displays P-ERK levels in an EGFR-mutant PDX exposed to panitumumab (PAN).
fromNews Center
2 months agoIdentifying Mechanisms Supporting Nanoparticle Therapy for Autoimmune Diseases - News Center
We knew that if you inject these nanoparticles into an animal model, the nanoparticles get taken up by antigen presenting cells and this resulted in increased regulatory T-cells and decreased inflammatory disease. However, we did not know how this happens,
Science
Cancer
fromenglish.elpais.com
1 month agoDouglas Hanahan, biologist: We don't necessarily need a cure, what we really need is cancer without disease'
Cancer cells acquire hallmarks: uncontrolled proliferation, evasion of growth barriers, resistance to programmed death, and relative immortality, driving tumor diversity and treatment variability.
fromNature
2 months agoMicrobiota-induced T cell plasticity enables immune-mediated tumour control - Nature
Although specific bacterial taxa have been associated with favourable clinical responses to immune checkpoint blockade (ICB) in cancer patients12,13,18,19,20,21,22, the mechanisms by which the intestinal microbiota influences anti-tumour immune responses remain poorly defined. Products of the microbiota, including metabolites23,24,25 and innate receptor ligands26, may reprogramme myeloid cells27, lowering the activation threshold for antigen presentation and thereby facilitating priming and activation of tumour-reactive T cells.
Cancer
Medicine
fromwww.theguardian.com
2 months agoSimple blood test can predict which breast cancer treatment will work best, study finds
A blood test measuring circulating tumour DNA predicts breast cancer treatment response before or within four weeks, enabling alternative therapies and avoiding ineffective drugs.
fromArs Technica
2 months agomRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say
As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.
Medicine
fromenglish.elpais.com
2 months agoA vaccine to prevent colon cancer shows promising results
Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.
Medicine
[ Load more ]